Literature DB >> 28235984

[Chronic skin ulcer in a 24-year-old man after a journey to Southeast Asia].

A Rueda Guzmán1, G Slesak2, R Fleck2, R Ignatius3,4, R Oehme5, J Schäfer2.   

Abstract

Our report concerns a 24-year-old man with a chronic exsudative skin lesion after a journey to Southeast Asia. The diagnosis of melioidosis was made by the identification of Burkholderia pseudomallei from the ichor. The diagnosis was confirmed by polymerase change reaction. The patient was treated with meropenem i. v. for about 10 days and with trimethoprim/sulfamethoxazole for the following 12 weeks. Melioidosis is an endemic disease in Southeast Asia and North Australia which in some cases can run a severe course and can have a high fatality rate. The relevance of melioidosis becomes more important against the background of the increasing global movement of travelers and migration.

Entities:  

Keywords:  Burkholderia pseudomallei; Melioidosis; Meropenem; Pneumonia; Trimethoprim, sulfamethoxazole drug combination

Mesh:

Substances:

Year:  2017        PMID: 28235984     DOI: 10.1007/s00108-017-0215-2

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  11 in total

Review 1.  Melioidosis.

Authors:  W Joost Wiersinga; Bart J Currie; Sharon J Peacock
Journal:  N Engl J Med       Date:  2012-09-13       Impact factor: 91.245

2.  Trimethoprim/sulfamethoxazole resistance in clinical isolates of Burkholderia pseudomallei.

Authors:  Vanaporn Wuthiekanun; Allen C Cheng; Wirongrong Chierakul; Premjit Amornchai; Direk Limmathurotsakul; Wipada Chaowagul; Andrew J H Simpson; Jennifer M Short; Gumphol Wongsuvan; Bina Maharjan; Nicholas J White; Sharon J Peacock
Journal:  J Antimicrob Chemother       Date:  2005-05-10       Impact factor: 5.790

Review 3.  Melioidosis: evolving concepts in epidemiology, pathogenesis, and treatment.

Authors:  Bart J Currie
Journal:  Semin Respir Crit Care Med       Date:  2015-02-02       Impact factor: 3.119

Review 4.  Melioidosis.

Authors:  N J White
Journal:  Lancet       Date:  2003-05-17       Impact factor: 79.321

5.  Recurrent melioidosis in the Darwin Prospective Melioidosis Study: improving therapies mean that relapse cases are now rare.

Authors:  Derek S Sarovich; Linda Ward; Erin P Price; Mark Mayo; Matthew C Pitman; Robert W Baird; Bart J Currie
Journal:  J Clin Microbiol       Date:  2013-11-27       Impact factor: 5.948

Review 6.  Cutaneous melioidosis in the tropical top end of Australia: a prospective study and review of the literature.

Authors:  Katherine B Gibney; Allen C Cheng; Bart J Currie
Journal:  Clin Infect Dis       Date:  2008-09-01       Impact factor: 9.079

Review 7.  Treatment and prophylaxis of melioidosis.

Authors:  David Dance
Journal:  Int J Antimicrob Agents       Date:  2014-02-03       Impact factor: 5.283

8.  Intravenous therapy duration and outcomes in melioidosis: a new treatment paradigm.

Authors:  Matthew C Pitman; Tara Luck; Catherine S Marshall; Nicholas M Anstey; Linda Ward; Bart J Currie
Journal:  PLoS Negl Trop Dis       Date:  2015-03-26

9.  Predicted global distribution of Burkholderia pseudomallei and burden of melioidosis.

Authors:  Direk Limmathurotsakul; Nick Golding; David A B Dance; Jane P Messina; David M Pigott; Catherine L Moyes; Dionne B Rolim; Eric Bertherat; Nicholas P J Day; Sharon J Peacock; Simon I Hay
Journal:  Nat Microbiol       Date:  2016-01-11       Impact factor: 17.745

10.  Workshop on treatment of and postexposure prophylaxis for Burkholderia pseudomallei and B. mallei Infection, 2010.

Authors:  Rebecca Lipsitz; Susan Garges; Rosemarie Aurigemma; Prasith Baccam; David D Blaney; Allen C Cheng; Bart J Currie; David Dance; Jay E Gee; Joseph Larsen; Direk Limmathurotsakul; Meredith G Morrow; Robert Norton; Elizabeth O'Mara; Sharon J Peacock; Nicki Pesik; L Paige Rogers; Herbert P Schweizer; Ivo Steinmetz; Gladys Tan; Patrick Tan; W Joost Wiersinga; Vanaporn Wuthiekanun; Theresa L Smith
Journal:  Emerg Infect Dis       Date:  2012-12       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.